Pharmacogenomics Market Size, Share, Growth & Industry Analysis, By Test Type (Genetic Testing, Pharmacogenomic Services, Diagnostic Kits), By Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Others), By End-User Industry (Hospitals, Clinics, Research & Academic Institutes, Pharmaceutical Companies), and Regional Analysis, 2024-2031

1 INTRODUCTION OF THE GLOBAL PHARMACOGENOMICS MARKET
1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Limitations
1.5 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 Data Collection
3.1.1 Secondary Sources
3.1.2 Primary Sources
3.1.3 Research Flow
3.2 Subject Matter Expert Advice
3.3 Quality Check
3.4 Final Review
3.5 Bottom-Up Approach
3.6 Top-down Approach

4 GLOBAL PHARMACOGENOMICS MARKET OUTLOOK
4.1 Market Evolution
4.2 Overview
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.3.4 Challenges
4.4 Pricing Analysis
4.5 Porter’s Five Forces Analysis
4.6 Value Chain Analysis
4.7 Macroeconomic Analysis

5 IMPACT OF RUSSIA-UKRAINE WAR

6 GLOBAL PHARMACOGENOMICS MARKET, BY TEST TYPE
6.1 Overview
6.2 Genetic Testing
6.3 Pharmacogenomic Services
6.4 Diagnostic Kits

7 GLOBAL PHARMACOGENOMICS MARKET, BY APPLICATION
7.1 Overview
7.2 Oncology
7.3 Cardiovascular Diseases
7.4 Neurological Disorders
7.5 Infectious Diseases
7.6 Others

8 GLOBAL PHARMACOGENOMICS MARKET, BY END-USER
8.1 Overview
8.2 Hospitals
8.3 Clinics
8.4 Research & Academic Institutes
8.5 Pharmaceutical Companies

9 GLOBAL PHARMACOGENOMICS MARKET, BY GEOGRAPHY
9.1 Overview

10 NORTH AMERICA
10.1 U.S.
10.2 Canada
10.3 Mexico

11 EUROPE
11.1 Germany
11.2 UK
11.3 France
11.4 Italy
11.5 Spain
11.6 Russia
11.7 Rest of Europe

12 ASIA-PACIFIC
12.1 China
12.2 Japan
12.3 India
12.4 South Korea
12.5 Rest of Asia-Pacific

13 MIDDLE EAST & AFRICA
13.1 GCC
13.2 South Africa
13.3 North Africa
13.4 Rest of Middle East & Africa

14 LATIN AMERICA
14.1 Brazil
14.2 Argentina
14.3 Rest of South America

15 GLOBAL PHARMACOGENOMICS MARKET COMPETITIVE LANDSCAPE
15.1 Overview
15.2 Key Developments
15.3 Key Strategic Developments
15.4 Company Market Ranking
15.5 Regional Footprint
15.6 Industry Footprint

16 COMPANY PROFILES
16.1 Thermo Fisher Scientific
16.1.1 Key Facts
16.1.2 Financial Overview
16.1.3 Product Benchmarking
16.1.4 Recent Developments
16.1.5 Winning Imperatives
16.1.6 Current Focus & Strategies
16.1.7 Threat from competition
16.1.8 SWOT Analysis
16.2 Roche
16.2.1 Key Facts
16.2.2 Financial Overview
16.2.3 Product Benchmarking
16.2.4 Recent Developments
16.2.5 Winning Imperatives
16.2.6 Current Focus & Strategies
16.2.7 Threat from competition
16.2.8 SWOT Analysis
16.3 Illumina
16.3.1 Key Facts
16.3.2 Financial Overview
16.3.3 Product Benchmarking
16.3.4 Recent Developments
16.3.5 Winning Imperatives
16.3.6 Current Focus & Strategies
16.3.7 Threat from competition
16.3.8 SWOT Analysis
16.4 Qiagen
16.4.1 Key Facts
16.4.2 Financial Overview
16.4.3 Product Benchmarking
16.4.4 Recent Developments
16.4.5 Winning Imperatives
16.4.6 Current Focus & Strategies
16.4.7 Threat from competition
16.4.8 SWOT Analysis
16.5 Abbott Laboratories
16.5.1 Key Facts
16.5.2 Financial Overview
16.5.3 Product Benchmarking
16.5.4 Recent Developments
16.5.5 Winning Imperatives
16.5.6 Current Focus & Strategies
16.5.7 Threat from competition
16.5.8 SWOT Analysis
16.6 Agilent Technologies
16.6.1 Key Facts
16.6.2 Financial Overview
16.6.3 Product Benchmarking
16.6.4 Recent Developments
16.7 Myriad Genetics
16.7.1 Key Facts
16.7.2 Financial Overview
16.7.3 Product Benchmarking
16.7.4 Recent Developments
16.8 LabCorp
16.8.1 Key Facts
16.8.2 Financial Overview
16.8.3 Product Benchmarking
16.8.4 Recent Developments
16.9 PerkinElmer
16.9.1 Key Facts
16.9.2 Financial Overview
16.9.3 Product Benchmarking
16.9.4 Recent Developments
16.10 Foundation Medicine
16.10.1 Key Facts
16.10.2 Financial Overview
16.10.3 Product Benchmarking
16.10.4 Recent Developments

LIST OF TABLES

TABLE 1 Global Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 2 Global Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 3 Global Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 4 Global Pharmacogenomics Market Revenue, By Geography, 2021 – 2031 (USD Billion)
TABLE 5 North America Pharmacogenomics Market Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 6 North America Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 7 North America Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 8 North America Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 9 US Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 10 US Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 11 US Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 12 Canada Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 13 Canada Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 14 Canada Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 15 Mexico Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 16 Mexico Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 17 Mexico Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 18 Europe Pharmacogenomics Market Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 19 Europe Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 20 Europe Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 21 Europe Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 22 Germany Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 23 Germany Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 24 Germany Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 25 France Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 26 France Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 27 France Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 28 UK Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 29 UK Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 30 UK Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 31 Spain Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 32 Spain Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 33 Spain Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 34 Italy Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 35 Italy Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 36 Italy Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 37 Russia Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 38 Russia Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 39 Russia Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 40 Rest of Europe Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 41 Rest of Europe Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 42 Rest of Europe Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 43 Asia-Pacific Pharmacogenomics Market Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 44 Asia-Pacific Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 45 Asia-Pacific Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 46 Asia-Pacific Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 47 China Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 48 China Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 49 China Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 50 Japan Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 51 Japan Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 52 Japan Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 53 India Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 54 India Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 55 India Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 56 South Korea Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 57 South Korea Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 58 South Korea Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 59 Rest of Asia-Pacific Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 60 Rest of Asia-Pacific Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 61 Rest of Asia-Pacific Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 62 Middle East and Africa Pharmacogenomics Market Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 63 Middle East and Africa Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 64 Middle East and Africa Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 65 Middle East and Africa Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 66 GCC Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 67 GCC Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 68 GCC Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 69 North Africa Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 70 North Africa Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 71 North Africa Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 72 South Africa Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 73 South Africa Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 74 South Africa Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 75 Rest of Middle East & Africa Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 76 Rest of Middle East & Africa Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 77 Rest of Middle East & Africa Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 78 Latin America Pharmacogenomics Market Revenue, By Country, 2021 – 2031 (USD Billion)
TABLE 79 Latin America Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 80 Latin America Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 81 Latin America Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 82 Brazil Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 83 Brazil Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 84 Brazil Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 85 Argentina Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 86 Argentina Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 87 Argentina Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 88 Rest of Latin America Pharmacogenomics Market Revenue, By Test Type, 2021 – 2031 (USD Billion)
TABLE 89 Rest of Latin America Pharmacogenomics Market Revenue, By Application, 2021 – 2031 (USD Billion)
TABLE 90 Rest of Latin America Pharmacogenomics Market Revenue, By End-User, 2021 – 2031 (USD Billion)
TABLE 91 Company Market Ranking
TABLE 92 Regional Footprint
TABLE 93 Product Benchmarking
TABLE 94 Recent Developments
TABLE 95 Winning Imperatives

LIST OF FIGURES

FIG. 1 Market Segmentation
FIG. 2 Research Timeline
FIG. 3 Global Pharmacogenomics Market 2021-2031 (USD Billion)
FIG. 4 Global Pharmacogenomics Market Geographical Analysis (CAGR %)
FIG. 5 Global Pharmacogenomics Absolute Market Opportunity (USD Billion)
FIG. 6 Global Pharmacogenomics Market Attractiveness (USD Billion)
FIG. 7 Global Pharmacogenomics Market, By Test Type, 2021-2031 (USD Billion)
FIG. 8 Global Pharmacogenomics Market, By Application, 2021-2031 (USD Billion)
FIG. 9 Global Pharmacogenomics Market, By End-User, 2021-2031 (USD Billion)
FIG. 11 Research Methodology
FIG. 12 Research Process
FIG. 13 Bottom-Up Approach
FIG. 14 Top-Bottom Approach
FIG. 15 Market Dynamics Overview
FIG. 16 Porter's Five Forces Analysis
FIG. 17 Value Chain Analysis
FIG. 18 Macroeconomic Analysis
FIG. 19 Global Pharmacogenomics Market Revenue Share, By Test Type, 2021 and 2031 (%)
FIG. 20 Global Pharmacogenomics Market Revenue Share, By Application, 2021 and 2031 (%)
FIG. 21 Global Pharmacogenomics Market Revenue Share, By End-User, 2021 and 2031 (%)
FIG. 22 Global Pharmacogenomics Market Revenue Share, By Geographic Regions, 2021 and 2031 (%)
FIG. 23 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 24 North America Pharmacogenomics Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 25 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 26 Europe Pharmacogenomics Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 27 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 28 Asia-Pacific Pharmacogenomics Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 29 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 30 Middle East & Africa Pharmacogenomics Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 31 Market Size and Projections, 2021 - 2031 (USD Billion)
FIG. 32 Latin America Pharmacogenomics Market Overview Share, By Countries, 2021 – 2031 (%)
FIG. 33 Key Strategic Development
FIG. 34 Key Facts
FIG. 35 Financial Overview
FIG. 36 SWOT Analysis